Please enable JavaScript to continue using this application.

Compare $ALXO vs $CHRS | Chartloom

Compare

$ALXO vs $CHRS

ALX Oncology Holdings Inc · Coherus Oncology Inc

ALXO

ALX Oncology Holdings Inc

CHRS

Coherus Oncology Inc

Compare $ALXO vs $CHRS

Comparing ALX Oncology Holdings Inc and Coherus Oncology Inc

ALXOALX Oncology Holdings Inc

CHRSCoherus Oncology Inc

ALXOALX Oncology Holdings Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

8.7%

52W performance

-36.5%

FCF yield

-42.2%

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALXO

CHRS

Detailed metrics comparison

ALXO

ALX Oncology Holdings Inc

CHRS

Coherus Oncology Inc

Market Cap

ALXO$168M

CHRS$165M

Enterprise Value

ALXO$156M

CHRS$134M

Price

ALXO$1.25

CHRS$1.07

P/E Ratio

ALXON/A

CHRSN/A

P/S Ratio

ALXO46.09x

CHRS3.24x

EV/Sales

ALXO0.00x

CHRS2.63x

EV/EBITDA

ALXO0.00x

CHRS2.57x

P/B Ratio

ALXO1.24x

CHRS2.95x

P/FCF Ratio

ALXON/A

CHRSN/A

EV/FCF

ALXO-2.20x

CHRS-0.72x

PEG Ratio

ALXON/A

CHRSN/A

Forward P/E (NTM)

ALXON/A

CHRSN/A

Forward P/S (NTM)

ALXON/A

CHRS2.04x

Revenue (TTM)

ALXO$0

CHRS$51M

Revenue Growth (YoY)

ALXON/A

CHRS-64.3%

Forward Rev Growth

ALXO357.6%

CHRS67.8%

Gross Margin (TTM)

ALXO9.0%

CHRS68.9%

Operating Margin (TTM)

ALXO0.0%

CHRS0.0%

EBITDA Margin (TTM)

ALXO0.0%

CHRS-288.0%

Net Margin (TTM)

ALXO0.0%

CHRS-259.4%

FCF Margin (TTM)

ALXON/A

CHRS-365.2%

Net Income (TTM)

ALXO$-81M

CHRS$-132M

FCF (TTM)

ALXO$-71M

CHRS$-186M

EPS (TTM)

ALXO-$0.60

CHRS-$0.85

ROE (TTM)

ALXO-9030.0%

CHRS-18336.0%

ROA (TTM)

ALXO-6728.0%

CHRS-4290.0%

ROIC (TTM)

ALXO-8046.0%

CHRS-10716.0%

Cash

ALXO$23M

CHRS$83M

Debt

ALXO$11M

CHRS$52M

Net Cash/Debt

ALXO$12M

CHRS$31M

Current Ratio (TTM)

ALXO9.71x

CHRS1.77x

Quick Ratio (TTM)

ALXO9.44x

CHRS1.58x

Debt/Equity (TTM)

ALXO0.08x

CHRS0.85x

Debt/Assets (TTM)

ALXO0.0%

CHRS0.0%

Interest Coverage (TTM)

ALXON/A

CHRSN/A

Net Debt/EBITDA (TTM)

ALXO0.00x

CHRS0.00x

Beta

ALXO0.55

CHRS0.99

52W Performance

ALXO-36.5%

CHRS-39.2%

YTD Performance

ALXO8.7%

CHRS-21.9%

% from 52W High

ALXO-53.0%

CHRS-59.1%

% from 52W Low

ALXO19.0%

CHRS9.9%

Asset Turnover (TTM)

ALXO0.00x

CHRS0.17x

FCF Yield (TTM)

ALXO-42.2%

CHRS-112.7%

Earnings Yield (TTM)

ALXO-48.1%

CHRS-80.1%

Dividend Yield (TTM)

ALXON/A

CHRSN/A

Rule of 40

ALXO0.0

CHRS-429.5

EV/GP/RG

ALXON/A

CHRS0.05

Ticker research

View ALXO research View CHRS research

Metric	ALXO ALX Oncology Holdings Inc	CHRS Coherus Oncology Inc
Market & Valuation
Market Cap	$168M	$165M
Enterprise Value	$156M	$134M
Price	$1.25	$1.07
P/E Ratio	N/A	N/A
P/S Ratio	46.09x	3.24x
EV/Sales	0.00x	2.63x
EV/EBITDA	0.00x	2.57x
P/B Ratio	1.24x	2.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-0.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.04x
Revenue & Growth
Revenue (TTM)	$0	$51M
Revenue Growth (YoY)	N/A	-64.3%
Forward Rev Growth	357.6%	67.8%
Profitability
Gross Margin (TTM)	9.0%	68.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-288.0%
Net Margin (TTM)	0.0%	-259.4%
FCF Margin (TTM)	N/A	-365.2%
Net Income (TTM)	$-81M	$-132M
FCF (TTM)	$-71M	$-186M
EPS (TTM)	-$0.60	-$0.85
ROE (TTM)	-9030.0%	-18336.0%
ROA (TTM)	-6728.0%	-4290.0%
ROIC (TTM)	-8046.0%	-10716.0%
Financial Health
Cash	$23M	$83M
Debt	$11M	$52M
Net Cash/Debt	$12M	$31M
Current Ratio (TTM)	9.71x	1.77x
Quick Ratio (TTM)	9.44x	1.58x
Debt/Equity (TTM)	0.08x	0.85x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	0.99
52W Performance	-36.5%	-39.2%
YTD Performance	8.7%	-21.9%
% from 52W High	-53.0%	-59.1%
% from 52W Low	19.0%	9.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.17x
FCF Yield (TTM)	-42.2%	-112.7%
Earnings Yield (TTM)	-48.1%	-80.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-429.5
EV/GP/RG	N/A	0.05
Ticker research	View ALXO research	View CHRS research

Valuation

P/S Ratio

CHRS

3.24x

ALXO

46.09x

EV/FCF

ALXO

-2.20x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

ALXO

357.6%

CHRS

67.8%

Profitability & performance

Gross Margin

CHRS

68.9%

ALXO

9.0%

ROE

ALXO

-9030.0%

CHRS

-18336.0%

FCF Yield %

ALXO

-42.2%

CHRS

-112.7%

52-Week Performance

ALXO

-36.5%

CHRS

-39.2%

Detailed metrics comparison

ALXO

ALX Oncology Holdings Inc

CHRS

Coherus Oncology Inc

Market Cap

ALXO$168M

CHRS$165M

Enterprise Value

ALXO$156M

CHRS$134M

Price

ALXO$1.25

CHRS$1.07

P/E Ratio

ALXON/A

CHRSN/A

P/S Ratio

ALXO46.09x

CHRS3.24x

EV/Sales

ALXO0.00x

CHRS2.63x

EV/EBITDA

ALXO0.00x

CHRS2.57x

P/B Ratio

ALXO1.24x

CHRS2.95x

P/FCF Ratio

ALXON/A

CHRSN/A

EV/FCF

ALXO-2.20x

CHRS-0.72x

PEG Ratio

ALXON/A

CHRSN/A

Forward P/E (NTM)

ALXON/A

CHRSN/A

Forward P/S (NTM)

ALXON/A

CHRS2.04x

Revenue (TTM)

ALXO$0

CHRS$51M

Revenue Growth (YoY)

ALXON/A

CHRS-64.3%

Forward Rev Growth

ALXO357.6%

CHRS67.8%

Gross Margin (TTM)

ALXO9.0%

CHRS68.9%

Operating Margin (TTM)

ALXO0.0%

CHRS0.0%

EBITDA Margin (TTM)

ALXO0.0%

CHRS-288.0%

Net Margin (TTM)

ALXO0.0%

CHRS-259.4%

FCF Margin (TTM)

ALXON/A

CHRS-365.2%

Net Income (TTM)

ALXO$-81M

CHRS$-132M

FCF (TTM)

ALXO$-71M

CHRS$-186M

EPS (TTM)

ALXO-$0.60

CHRS-$0.85

ROE (TTM)

ALXO-9030.0%

CHRS-18336.0%

ROA (TTM)

ALXO-6728.0%

CHRS-4290.0%

ROIC (TTM)

ALXO-8046.0%

CHRS-10716.0%

Cash

ALXO$23M

CHRS$83M

Debt

ALXO$11M

CHRS$52M

Net Cash/Debt

ALXO$12M

CHRS$31M

Current Ratio (TTM)

ALXO9.71x

CHRS1.77x

Quick Ratio (TTM)

ALXO9.44x

CHRS1.58x

Debt/Equity (TTM)

ALXO0.08x

CHRS0.85x

Debt/Assets (TTM)

ALXO0.0%

CHRS0.0%

Interest Coverage (TTM)

ALXON/A

CHRSN/A

Net Debt/EBITDA (TTM)

ALXO0.00x

CHRS0.00x

Beta

ALXO0.55

CHRS0.99

52W Performance

ALXO-36.5%

CHRS-39.2%

YTD Performance

ALXO8.7%

CHRS-21.9%

% from 52W High

ALXO-53.0%

CHRS-59.1%

% from 52W Low

ALXO19.0%

CHRS9.9%

Asset Turnover (TTM)

ALXO0.00x

CHRS0.17x

FCF Yield (TTM)

ALXO-42.2%

CHRS-112.7%

Earnings Yield (TTM)

ALXO-48.1%

CHRS-80.1%

Dividend Yield (TTM)

ALXON/A

CHRSN/A

Rule of 40

ALXO0.0

CHRS-429.5

EV/GP/RG

ALXON/A

CHRS0.05

Ticker research

View ALXO research View CHRS research

Metric	ALXO ALX Oncology Holdings Inc	CHRS Coherus Oncology Inc
Market & Valuation
Market Cap	$168M	$165M
Enterprise Value	$156M	$134M
Price	$1.25	$1.07
P/E Ratio	N/A	N/A
P/S Ratio	46.09x	3.24x
EV/Sales	0.00x	2.63x
EV/EBITDA	0.00x	2.57x
P/B Ratio	1.24x	2.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.20x	-0.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.04x
Revenue & Growth
Revenue (TTM)	$0	$51M
Revenue Growth (YoY)	N/A	-64.3%
Forward Rev Growth	357.6%	67.8%
Profitability
Gross Margin (TTM)	9.0%	68.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-288.0%
Net Margin (TTM)	0.0%	-259.4%
FCF Margin (TTM)	N/A	-365.2%
Net Income (TTM)	$-81M	$-132M
FCF (TTM)	$-71M	$-186M
EPS (TTM)	-$0.60	-$0.85
ROE (TTM)	-9030.0%	-18336.0%
ROA (TTM)	-6728.0%	-4290.0%
ROIC (TTM)	-8046.0%	-10716.0%
Financial Health
Cash	$23M	$83M
Debt	$11M	$52M
Net Cash/Debt	$12M	$31M
Current Ratio (TTM)	9.71x	1.77x
Quick Ratio (TTM)	9.44x	1.58x
Debt/Equity (TTM)	0.08x	0.85x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	0.99
52W Performance	-36.5%	-39.2%
YTD Performance	8.7%	-21.9%
% from 52W High	-53.0%	-59.1%
% from 52W Low	19.0%	9.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.17x
FCF Yield (TTM)	-42.2%	-112.7%
Earnings Yield (TTM)	-48.1%	-80.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-429.5
EV/GP/RG	N/A	0.05
Ticker research	View ALXO research	View CHRS research